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Abstract: Rheumatoid arthritis (RA) is a chronic autoimmune disease targeting multiple joints. The synovium is the 
primary site of the inflammatory process, which if untreated leads to irreversible damage to the adjacent cartilage and 
bone. It is now well established that autoantibodies that are characteristic of RA, including rheumatoid factor (RF) and 
anti-citrulluninated protein antibodies (ACPA), are present before clinical disease onset. Studies in both humans and 
animal models are beginning to provide new insights into how this asymptomatic autoimmunity evolves into an 
inflammatory process that is localized in the synovium. 
Once RA synovitis established, a number of amplification mechanisms serve to sustain the process leading to the 
persistence of the disease. These mechanisms include engagement of the resident mesenchymal cells and the 
establishment of ectopic lymphoid structures in the synovium, although the relationship between these lymphoid 
structures and the presence of RA autoantibodies remains unclear. 
An enhanced understanding of the mechanisms that initiate and sustain RA synovitis offers unprecedented opportunities 
for therapeutics, and ultimately prevention strategies. 
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INTRODUCTION 
  The transition from normal to non-specific inflammatory 
synovium and subsequently to established rheumatoid 
arthritis synovium is the result of a break in immune 
tolerance both systemically and at the level of the synovial 
tissue. The presence of circulating ACPA and RF years prior 
to the onset of clinical symptoms [1, 2] and early histological 
changes in the (presumed) unaffected joints of RA patients 
[3, 4] indicates that the early stages of this immune tolerance 
breakdown are subclinical. The importance of mediators of 
innate immunity in initiating synovial responses is being 
increasingly recognized. Recent progress has been made in 
elucidating the mechanisms involved in bridging the innate 
and adaptive immune systems leading to persistent synovitis, 
however our understanding of these mechanisms is still 
incomplete. This review will describe the main 
histopathological and immunohistologic features of RA 
synovitis, and will address some potentially important 
mechanisms that may facilitate the initiation and progression 
of rheumatoid arthritis synovitis. 
PRE-CLINICAL STAGE OF RA 
  Circulating autoantibodies to citrullinated proteins 
(ACPA) can be detected several years prior to the onset of 
joint symptoms [1, 2] and examination of pre-disease cohorts 
of patients at risk for future RA has suggested a progression 
in the fine specificity of these responses consistent with 
epitope spreading [5]. This phenomenon has also been 
demonstrated in other autoimmune disorders such as   
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systemic lupus erythematosus [6]. Citrullination itself is not 
unique to RA tissues, and indeed is a normal physiological 
process. While the source of the citrullinated protein 
autoantigens in established RA appears to be in the 
synovium [7, 8], extra-articular sites such as the lungs [9], or 
skin [10], are also potential sources. Isoforms of 
peptidylarginine deiminase (PAD), the enzyme responsible 
for post-translational conversion of arginine to citrulline in 
peptides, are found in a variety of cells and tissues [11-17], 
however to date only PAD2 and PAD4 have been found in 
synovium [7, 18]. PAD4 expression seems to be more 
specific for RA tissue, however the expression of both PAD2 
and PAD 4 correlate with the degree of inflammation. Thus 
the development of immune responses to citrullinated 
proteins as indicated by the presence of ACPAs is highly 
suggestive of a break in immune tolerance that precedes the 
onset of clinically detectable synovitis. 
NON-SPECIFIC SYNOVITIS, IMMUNE COMPLEXES 
AND INNATE IMMUNITY 
  Studies of the earliest stages of synovitis have mostly 
relied on animal models of rheumatoid-like inflammatory 
arthritis and although the direct application/attribution to 
human disease should be interpreted with some caution, 
these studies provide valuable insights into early 
pathogenesis. In the G6PI (KBxN) immune transfer mouse 
model of rheumatoid arthritis, components of the innate 
immune system including mast cells [19, 20], complement 
[21], Fc receptors [22], and cytokines such as IL-1 and TNF 
[23] are critical for the development of synovitis. In this 
model, the formation of immune complexes appears to be an 
important initial step to allow pathogenic autoantibodies 
access to the synovium [24]. FCR-expressing cells in 
inflamed synovium may sense these circulating immune 
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preferentially in the distal extremities. On this basis, it is 
proposed that distal extremity vessels may have unique 
properties and that the increased vasopermeability may also 
have an amplifying function in the early stages of synovitis 
allowing influx of inflammatory cells into the joint tissues. It 
is well known that immune complexes are present in blood 
and synovial fluid of patients with established RA, but their 
role in the early stages of the disease is less clear. It has been 
shown that in a significant proportion of ACPA positive RA 
patients these circulating immune complexes contain 
citrullinated fibrinogen [25]. Immune complexes and 
citrullinated fibrinogen co-localize with complement 
component C3 in pannus tissue suggesting immune complex 
deposition and complement activation may lead to ongoing 
synovitis [25]. Recently, Monach et al. demonstrated that 
immune complexes deposited in synovium target a wide 
range of proteins some of which are histones and relatively 
specific for RA [26]. 
  The potential importance of immune complexes in 
initiating human disease is supported by an illustrative case 
report which describes the progression of an initially 
asymptomatic individual who was ACPA positive, and who 
subsequently developed synovitis [27]. Although anti-CCP 
antibodies preceded joint symptoms, the development of 
antibodies to citrullinated fibrinogen coincided with the 
appearance of joint symptoms. On synovial biopsy of an 
affected knee performed soon after symptom onset, the 
lining layer was markedly abnormal whereas the sublining 
layer showed a histologically normal vascular pattern, and 
minimal if any increased cellularity. In the lining layer there 
was evidence of immune deposits of IgG, IgA, C3, and fibrin 
which co-localized with intra-cellular citrullinated proteins, 
and with widespread lining cell apoptosis (Fig. 1). This 
supports the hypothesis that pre-existing ACPA may access 
synovial tissue early in disease perhaps at the time of non-
specific synovitis onset and that the synovial lining layer 
may be the primary target of the initial immune processes. It 
 
Fig. (1). Synovial tissue analysis of biopsy material obtained from a symptomatic knee joint shortly after onset of articular symptoms. A) 
H&E light microscopy showing marked disruption of the synovial lining cell layer. The lining cells appear to be floating in an amorphous 
extra-cellular matrix. The sublining stroma is relatively unremarkable with minimal evidence of inflammatory infiltration. B) Intracellular 
citrullinated antigens are detected by intense staining of the synovial lining cells using a polyclonal anti-citrulline antibody. There is less 
intense staining of the surrounding matrix. C) Immunofluoresence staining of synovial tissue for C3 showing positive staining in the lining 
layer. Similar results were seen with IgG, IgA, and fibrin staining. D) The synovial lining cells exhibit evidence for widespread apoptosis as 
detected by TUNEL staining. Original magnification x 200 for A), and x 400 for B), C), D). The Synovium in Rheumatoid Arthritis  The Open Rheumatology Journal, 2011, Volume 5   109 
can be further speculated that the immune mechanisms 
generating ACPA are then amplified with continued 
exposure to citrullinated synovial antigens. In a similar case 
series of very early arthritis with a mean disease duration 
less than 4 weeks, perivascular CD3 and CD4 T cells and a 
mild superficial infiltration of lymphocytes and macrophages 
were found, however there were no aggregates and 
vascularity was normal, again suggesting superficial 
structures such as the lining layer may be a primary site for 
disease pathogenesis [28]. 
DENDRITIC CELLS AND INNATE IMMUNITY IN 
RA SYNOVITIS 
  Dendritic cells (DC) are key players in innate immunity 
and may initiate and/or perpetuate synovitis by presenting 
arthritogenic antigens to components of the adaptive immune 
system [29-31]. Activation and maturation of DC occurs 
after exposure to multiple triggers including viral and 
bacterial products, cytokines, immune complexes, multiple 
endogenous ligands, and even disruption of cell-cell contact 
[32] and hypoxia [33]. Myeloid DC (mDC), and the more 
immature plasmacytoid DC (pDC) express distinct patterns 
of chemokine receptors and Toll-like receptors (TLR) [29, 
34]. Both mDC and pDC are present in inflamed synovial 
tissue, and are not specific to RA [35-37]. However the 
number of pDC is higher in RA synovium compared to OA 
synovium, particularly in synovium from patients who are 
RF or ACPA positive. This observation is consistent with the 
suggestion that pDC may be involved in the synovial 
immune responses leading to the local formation of RA 
autoantibodies. In RA synovium, DC are located in primarily 
in the sublining tissues near aggregates of CD3 and CD8 
cells [36], and adjacent to blood vessels [35]. Synovial pDC 
retain an immature phenotype and express IL-18 and IL-15, 
which may contribute to synovial inflammation and further 
DC recruitment, whereas synovial mDC produce IL-23 
which may promote Th17 cell expansion [36]. The 
proportion of mature mDC increases with increasing grade 
of inflammation [37], possibly reflecting ongoing 
recruitment and activation of DC in persistent disease. 
FIBROBLAST-LIKE SYNOVIOCYTES AS MEDIA-
TORS OF INNATE IMMUNITY IN RA SYNOVITIS 
  RA fibroblast-like synoviocytes (FLS) express several 
TLR, suggesting they may contribute to the innate immune 
responses initiating and/or perpetuating RA synovitis. TLR3 
and TLR4 in particular are highly expressed in RA 
synovium, even at an early stage of disease, and are found 
predominantly in the lining layer, occasionally extending 
into the sublining and perivascular areas [38]. TLR3 
stimulation of RA FLS leads to increased expression of 
inflammatory cytokines such as IL-6, and to matrix 
degrading enzymes such as MMP3 and MMP13 [38]. A 
number of endogenous ligands stimulate TLR pathways in 
RA FLS [39], and can thus serve to activate these cells. 
TRANSITION FROM EARLY NON-SPECIFIC SYNO-
VITIS TO ESTABLISHED RA SYNOVITIS 
  Key histological features of RA including synovial lining 
layer hypertrophy, sublining infiltration with mononuclear 
cells, increased vascularity and fibrin deposition are seen in 
patients reporting as little as 6 weeks or less of symptoms 
and in the unaffected joints of patients with active synovitis 
[3, 4], whereas organized lymphoid follicles and pannus 
tissue are features generally associated with established RA 
synovium (Fig. 2). As previously described, abnormalities of 
the synovial lining layer may be a very early feature of 
synovitis. Even in early clinical disease, the surface of the 
lining layer is often covered with fibrin deposits generated 
from the activation of the fibrinolytic system by synovial 
fluid. Indeed, the lining layer may be completely replaced by 
a fibrin cap, and in highly inflamed tissues this fibrin can 
extend deep into the sublining layers. In very early disease 
the sublining infiltrates may be minimal or modest [27, 28]. 
At this stage, macrophages [3], and an infiltration by natural 
killer cells has been described [40]. Diffuse mononuclear 
infiltrates and small lymphoid aggregates are seen in both 
early and late RA. However, as discussed in detail below, 
aggregates resembling lymphoid follicles with germinal 
centers are typically seen only in well established disease. 
The synovium obtained from ACPA positive RA patients 
tends to have more ectopic germinal centers and reduced 
fibrosis compared to synovium from ACPA negative 
patients, regardless of disease duration [41, 42], although 
other studies could not confirm these observations [43-45]. 
Pannus, the highly destructive tissue present at the interface 
between synovium, cartilage, and bone is a characteristic 
feature of erosive RA and contains large numbers of 
macrophages and fibroblasts that express high levels of 
proteases. Osteoclasts derived from pannus tissue can be 
detected at the interface of bone and cartilage (Fig. 3). 
  Vascular patterns are also established early in disease and 
may serve to distinguish RA from other non-RA 
arthropathies [46, 47]. In established RA, vascular structures 
are prominent especially in the deep sublining areas 
presumably related to increased angiogenesis. Immature 
blood vessels can be found early in disease but are even 
more numerous in patients with erosive disease of longer 
duration indicating ongoing angiogenesis [48]. Despite 
evidence of angiogenesis, morphometric studies indicate 
there are relatively fewer blood vessels in sites adjacent to 
the expanded lining layer which when combined with the 
increased metabolic demands of the highly cellular 
structures, suggests relative hypoxia [49]. Hypoxia is a 
potent stimulus for the production of VEGF and other 
angiogenesis mediators which are highly expressed in 
inflamed RA synovium [50-52]. The vascular endothelium is 
activated by pro-inflammatory mediators to express adhesion 
molecules such as E-selectin, P-selectin, and ICAM1 that are 
involved in the recruitment of inflammatory cells. 
Synoviocytes also express adhesion molecules including 
VCAM1, VLA4, PECAM1 and ICAM1. These molecules 
are expressed equally in synovium from patients with early 
(<1 year symptoms) and late RA [53]. It is likely that 
adhesion molecules play a role in initiating and maintaining 
synovial infiltrates by recruiting inflammatory cells through 
the endothelium and then retaining inflammatory cells in the 
synovium through adherence to matrix cells and other 
synovial structures. 
  Histological comparisons of synovial tissue obtained 
from patients that have been matched for disease activity and 
treatment have shown no difference in cellular infiltration 
between those with early (<1 year) or late (>5 years) disease  
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[54, 55]. Similarly, cytokine expression [56] and adhesion 
molecule expression [53] is similar between early and late 
disease. This supports the hypothesis that the earliest 
synovial pathology is subclinical, the duration of subclinical 
disease may be variable and that at the time of symptom 
onset, clinical assessment and subsequent tissue biopsy, the 
 
Fig. (2). Histopathology of RA synovitis. (A) lymphoid aggregate; (B) Diffuse lymphocytes infiltrate; (C) Hyperplasia of the lining layer; 
(D) Fibrin cap replacing a denuded lining layer. 
 
Fig. (3). Interface between pannus tissue and bone in a patient with RA. (A) the synovial lesion is invading the adjacent bone. (B) Staining 
for tartrate resistant acid phosphatase in the circled area demonstrates the presence of osteoclasts. The Synovium in Rheumatoid Arthritis  The Open Rheumatology Journal, 2011, Volume 5   111 
synovitis is already in a chronic stage [57]. In the absence of 
serial sampling of joints that progress from asymptomatic to 
minimally symptomatic to definite clinical synovitis to 
erosive synovitis it is difficult to assess the true histological 
progression of disease. Such studies are difficult to perform. 
ECTOPIC LYMPHOID NEOGENESIS IN RA 
SYNOVIUM 
  One of the important unanswered questions in RA 
pathogenesis is how the systemic autoimmunity that 
precedes the clinical onset of RA becomes localized and 
amplified in the joints. To address this key question, a 
number of studies have aimed to develop a better 
understanding of ectopic lymphoid neogenesis, a process 
whereby lymphoid structures resembling those present in 
secondary lymphoid tissues become established in target 
tissues such as RA synovium. Research in this area has 
generated a number of important observations: 
1)  Fully developed lymphoid aggregates with functional 
germinal centres are found in ~25% of RA synovial 
tissue samples, typically those derived from 
individuals with well established disease [44, 45, 58-
62]. One hypothesis has suggested that the capacity to 
form these ectopic lymphoid structures in the 
synovium is an inherent property of the disease 
process in a subset of RA patients and one that is 
retained throughout the duration of the disease [60, 
62]. Other viewpoints suggest that these structures are 
a non-specific reflection of the chronicity and severity 
of the disease, are not indicative of a unique 
immunopathologic process in a subset of RA patients 
[44, 45, 61] and may be reversible [43]. It should be 
added that ectopic lymphoid structures are by no 
means unique to rheumatoid synovitis, and have been 
well described in a spectrum of other chronic 
autoimmune diseases. 
2)  Several key cytokines and chemokines have been 
shown to be involved in the formation of ectopic 
lymphoid structures in the synovium. These include 
CXCL13, CCL21, LT, [62-65]. The chemokine 
CXCL13 has been of particular interest since it is 
important in the recruitment of B cells, and was 
shown to be actively produced by antigen 
experienced synovial helper T cells [64]. 
3)  A recent detailed study of RA lymphoid aggregates 
indicates that synovial tissues with follicular 
structures characterized by the presence of follicular 
dendritic cell (FDC) networks express activation-
induced cytidine deaminase (AID), the enzyme 
required for somatic hypermutation and class-switch 
recombination of Ig genes [59]. These structures were 
found to be spatially associated with plasma cells that 
produce ACPA. Moreover, elegant experiments 
where human RA synovium was transplanted into 
SCID mice provided compelling evidence that these 
AID positive FDC structures support ongoing 
production of class-switched ACPA which were 
detectable in the sera of the mice, without any 
requirement for further recruitment of immune cells, 
particularly B cells, into the lymphoid structures. 
While this study provides evidence that ectopic 
lymphoid structures in the RA synovium are 
functional and support autoantibody maturation and 
production, several other large studies have failed to 
demonstrate an association between ectopic lymphoid 
structures in the synovium and B cell autoimmunity 
in RA [43-45]. In particular, ectopic lymphoid 
neogenesis is described in RF and ACPA negative 
RA [43], and in psoriatic arthritis [58]. Thus, it 
remains a challenge to clearly define the pathogenic 
significance of these synovial lesions, which are 
characteristic although not specific for RA. 
INTERACTIONS BETWEEN IMMUNE CELLS AND 
RESIDENT MESENCHYMAL CELLS IN THE 
SYNOVIUM 
  Irrespective of how the mononuclear cell infiltrate is 
arranged in the synovium, be it diffuse, aggregated, or with 
germinal centre formation, there is clearly close interaction 
between immune competent cells such as lymphocytes, 
macrophages, and DC with resident mesenchymal cells of 
the synovium such as FLS. The interactions between these 
cells are meditated by complex cytokine networks and by 
signaling events resulting from direct cell to cell contact. 
Much has been written about the former, as the study of 
cytokine effects on various cell types lends itself well to in 
vitro manipulation and experimentation. For example, the 
effects of key pro-inflammatory cytokines such as TNFa and 
IL1b have been exhaustively studied and exploited 
therapeutically. More recently, the recognition of the key 
pro-inflammatory role that the T cell cytokine IL-17 plays in 
RA synovitis, has generated similar investigative activity to 
better define the effects of this cytokine on cells in chronic 
inflammatory microenvironments such as the RA synovium 
(reviewed in [66, 67]). 
  In contrast to defining the effects of cytokines such as 
TNFa, IL-1b, and IL-17 on cell biology, the effects that are 
mediated by cell-cell contact are more subtle, and more 
difficult manipulate in vitro. The close in vivo juxtaposition 
of T cells, B cells, macrophages, dendritic cells, and FLS in 
the synovial microenvironment suggests that the signaling 
events mediated by direct cell-cell contact between these 
cells likely involve multiple partners simultaneously, a 
situation that is difficult to simulate in vitro. Nevertheless, an 
interesting recent study demonstrated that in vivo activated 
CD14+ monocytes derived from the inflamed joints of 
patients with active RA spontaneously and specifically 
promoted Th17, but not Th1 or Th2 responses, compared 
with resting CD14+ monocytes from the blood. These in vivo 
activated monocytes promoted Th17 responses in a cell-
contact dependent manner, and unlike Th17 stimulation by 
monocytes that were in vitro activated with 
lipopolysaccharide, intracellular IL-17 expression was TNF-
alpha- and IL-1beta-independent. These data suggest that 
newly recruited memory CD4 T cells can be induced to 
produce IL-17 after cell-cell interactions with activated 
monocytes in the synovium [68]. This mechanism may be 
particularly relevant in explaining the incomplete responses 
observed with TNFa inhibition and the recurrence of disease 
with withdrawal of therapy. 
  The interactions between immune/inflammatory cells and 
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between the inflammatory and destructive arms of RA 
synovitis. RA T cells, which have been shown to exhibit 
extensive features of premature senescence [69], aberrantly 
express the fractalkine (FKN) receptor CX3CR1 which 
interacts with FKN expressed on FLS. This interaction 
results in activation and enhanced survival of the T cells 
[70], as well as proliferation of the FLS [71]. A parallel 
interaction is mediated through the aberrant expression of 
natural-killer group 2, member D (NKG2D) and its ligand 
MIC expressed on FLS [72]. Such self-sustaining 
amplification loops between synovial T cells and FLS 
potentially plays a key role in the perpetuation of RA 
synovitis, while increasing its destructive potential. 
  Much has been learned over the past two decades about 
the biology of FLS and how they become “transformed” in 
the RA synovial microenvironment to become efficient 
matrix degrading cells that make a major contribution to the 
articular damage seen in RA joints. An important recent 
insight has been the identification of cadherin 11 as the 
adhesion molecule that mediates the homotypic aggregation 
of FLS in the synovial lining layer [73-75]. These studies 
have clearly shown that cadherin 11 is an important mediator 
of RA FLS invasiveness, and that inhibition of this molecule 
results in a dramatic amelioration to the articular damage 
caused by chronic synovitis. Additionally, SCID mouse 
studies have demonstrated the ability of human RA FLS to 
migrate and damage distal unaffected human cartilage in a 
process that may be facilitated by angiogenesis. Therapeutic 
exploitation of these observations may add substantially to 
the current armamentarium, which is focused primarily on 
inhibiting inflammatory mediators and cells rather than 
matrix degrading FLS. 
CONCLUSIONS 
  Recent insights obtained from animal models and studies 
of early and established RA synovial tissues have suggested 
potential mechanisms by which normal immune tolerance is 
interrupted leading to autoimmunity (Fig. 4). A non-specific 
insult could potentially trigger local innate immunity 
heralding the onset of clinical synovitis. In the setting of 
autoimmunity this inflammation persists leading to the 
formation of organized lymphoid structures and angiogenesis 
which serve to sustain the inflammatory synovium. In time, 
mesenchymal transformation and osteoclastogenesis lead to 
the destructive lesions characteristic of established RA. This 
paradigm suggests steps at which targeted intervention has 
the potential to significantly alter the course of disease and 
identifies structures and mechanisms which may be 
predictive of disease outcome or treatment response. 
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